Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multi-centre, Phase 1b Safety and Feasibility Study for the Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment (NeoBEMA)

NCT06978062 is registered in ClinicalTrials.gov with European Organisation for Research and Treatment of Cancer - EORTC as lead sponsor.

NCT NCT06978062
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06978062 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multi-centre, Phase 1b Safety and Feasibility Study for the Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment (NeoBEMA)
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Phase
Phase 1
Overall status
Not yet recruiting
Start date
February 20, 2026
Completion date
September 28, 2029
Enrollment
27 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal cancer